anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
1439462 Brightening teeth J M HALSTEAD (W A Drucker) 12 June 1973 [24 Aug 1972] 39601/72 Heading A5B Compositions for use in brightening the teeth comprise an aqueous solution buffered to pH 8 to 12 of an N-chloroamine (except N-monochloroglycine) reaction product of (i) at least one hypochlorite selected from alkali metal and alkaline earth metal hypochlorites e.g. having the formula MClO and/or M&lt;2&gt;Cl(ClO) and/or M&lt;2&gt;(ClO)2 where M is selected from Li, Na, K, Rb or Cs, and where M&lt;2&gt; is Ca, Sr or Ba; and (ii) a non-toxic watersoluble aminocarboxylic acid, aminosulphonic acid, alkanolamine or urea e.g. taurine, sulphamic acid, 2-aminoethanol, sarcosine, N- acetylglycine, alpha-aminoisobutyric acid and ethylenediamine tetraacetic acid. The solution may be obtained (i) by mixing an aqueous solution of the amine reactant with the hypochlorite or (ii) by adding a pre-prepared N- chloroamine to water. The solution may be obtained by dissolving in water a first tablet containing the hypochlorite and a second tablet containing the amine reactant and buffer, at least one of the tablets optionally including an effervescent material such as adipic acid and sodium bicarbonate. The molar ratio of amine to hypochlorite anion may be at least 1:2 and the concentration of hypochlorite anion is preferably 0.05 to 6% by weight. The composition may be in paste form and include a thickener such as SiO3 and the N-chloro amine in the solution may have a half-life of 3 to 60 minutes.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a contacting material for invigoration, useful for improving the health of family and connubial harmony to increase the offspring, free from side action and suitable for a person necessitating the consultation with a doctor in the case of taking a peroral drug having a side action risk and a person to prefer the plaster to oral administration owing to the poor liver action or the feeling of difficulty in taking a drug by oral administration.  &lt;P&gt;SOLUTION: A material having high elasticity and stretchability is kneaded with particles free from photocatalytic action, etc., and the mixture is formed in the form of a part of a male or female wear. Since the product is closely contactable with the skin, it has strong permeation effect of ions, etc., into the skin to quickly invigorate the body. The ion, etc., have blood flow increasing action in the body and the invigorating speed depends upon the contacting part of the body, however, the activity is increased by about 50% within 20-30 min. Since the compounded component such as ionic mineral is included by kneading, it is resistant to falling off, has high durability and is durable over a long period owing to the easy cleanability of dirt. It is free from side action and freely usable in contrast with a drug for peroral administration.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an aqueous solution containing a sulfur-containing compound contained in a plant of Liliaceae, in a high content.  &lt;P&gt;SOLUTION: This aqueous solution containing the sulfur-containing compound contained in the plant of Liliaceae is provided. More concretely, the aqueous solution containing the sulfur-containing compound is obtained by immersing the plant of Liliaceae in an aqueous solution and extracting under an acidic condition. The aqueous solution containing the sulfur-containing compound can contain e.g. the sulfur-containing compound peculiar to the plant of Liliaceae such as allysine, etc., in a high content, since the sulfur-containing compound can be extracted into the solution from the plant body of the plant of Liliaceae in a good efficiency. In order to obtain such the aqueous solution, it is preferable to use the plant belonging to the genus Allium of Liliaceae, containing the sulfur-containing compound richly, and further preferable to use garlic or onion.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
1472427 Process for alkali metal or ammonium insulin ELI LILLY &amp; CO 15 July 1974 [16 July 1973] 31199/74 Heading C3H Alkali metal insulin or ammonium insulin is prepared by a process which comprises (A) preparing an alkaline aqueous solution of a divalent metal insulin, a chelating agent for divalent metal ions, and alkali metal or ammonium ions, wherein the divalent metal is selected from the elements of Groups VIIB, VIII, IB and IIB of the Periodic Table of the elements, the concentration of divalent metal insulin is 10 to 1000 U/mg., the concentration of alkali metal or ammonium ions is 0À2 to 1À0 M, the pH of the solution is 7À6 to 8À6, the concentration of chelating agent is 0À0002 to 0À05 M, the molar ratio of chelating agent to divalent metal in the divalent metal insulin is at least 3 : 1, and the chelating agent has the general formula wherein R 1 , R 5  are monovalent organic radicals independently selected from carboxymethyl, carboxyethyl, C 1-6  alkyl, C 1-6  hydroxyalkyl; R 2  and R 6  are monovalent organic radicals independently selected from carboxymethyl, carboxyethyl; R 3  is a monovalent radical selected from hydrogen, hydroxy, C 1-6  alkyl; R 4  is a monovalent radical selected from hydrogen, carboxymethyl, carboxyethyl; m is 1 to 6; n is 0 or 1; p is 0 or 1, r is 2-6; s is 0 to 2; (B) crystallizing the alkali metal insulin or ammonium insulin. The preferred divalent metal is manganese, iron, cobalt, nickel, copper, zinc or cadmium and the preferred alkali metal is sodium. The preferred chelating agent is EDTA. The divalent metal insulin may contain 0 to 0À4% weight per volume of a preservative, such as phenol. Examples describe the preparation of (1)-(3) sodium insulin, (4) potassium insulin, (5) lithium insulin and (6) ammonium insulin. Polyacrylamide gel electrophoretic analysis indicates that the sodium insulin of Examples (2) and (3) is free from non-insulin proteins which are present in the starting material, sodium insulin, isolated from pork pancreas.
&#34;Process for obtaining indole derivatives, with particular substitution of the nitrogen atom of the indole nucleus&#34; characterized by the fact that, by its adoption, an indole substituted in N is obtained, using as a condensing agent phenyl sodium, more specifically, being the indoles to treat those corresponding to the general formula: ** (See formula) ** wherein R1-R2-R3-R4-R5-R6 represent, respectively: R1 can be H, or an alkyl radical of few carbon atoms, or a nitro group. R2 can be H, or an alkoxy group, or an alkyl group, of few carbon atoms. R3 can be H, or an alkyl. R 4 can be H or an alkyl group with a few carbon atoms. R5 can be a lower alkoxy, or a benzyloxy. And R6 is an H, which, after condensation, are treated successively with a halogenide of an aromatic or heterocyclic acid, substituted or not. (Machine-translation by Google Translate, not legally binding)
Disclosed is the composition for treating or curing diabetes mellitus containing an ingredient or component suitable for treatment of diabetes mellitus from an extract obtained by immersing a plant belonging to genus Tithonia and/or Ludwigia in a pharmacologically acceptable solvent for a predetermined period of time, said plant belonging to genus Tithonia being Tithonia diversifolia (Hemsl.) A. Gray, Tithonia rotundifolia (Mill) Blake, Tithonia fruticosa Canby &amp; Rose, Tithonia scaberrima Benth. or Tithonia longeradiata (Bertol) Brake; and said plant belonging to genus Ludwigia being Ludwigia octovalvis Raven or Ludwigia prostrata Roxb. or Ludwigia epilobioides Maxim. The composition administered in the form of tea or drink or other formulation to a diabetic patient by first applying a composition containing an extract from the plant belonging to genus Tithonia and thereafter applying a composition containing an extract from the plant belonging to genus Ludwigia. The composition for treating diabetes mellitus can alleviate or diminish a variety of symptoms caused by diabetes mellitus or prevailing among diabetic patients, thereby naturally reducing or lowering blood glucose levels to a normal range and preventing diabetes mellitus to be caused to reoccur for a long period of time without continuously administering the composition.
A liq. emollient for shaving contains &gt;=2 silicone fluids having viscosities in the range 5-5,000 centistokes, the viscosity of the mixt. being 110 plus-or-minus 10 centistokes, and 20-30% isopropyl myristate and 0.05-0.5% azulene. The mixt. is applied to the cutting edge of the dry razor, which is then used on previously wetted skin. Time consuming treatment of the skin with, e.g. shaving foams, is not necessary. The skin surface is not obscured, so cutting scars, warts etc. can be avoided. The blade can be rinsed to remove hairs without the need to reapply the compsn. which is sticky and hydrophobic.
Relating to microorganism fermented Chinese medicinal poultry drugs, the invention provides a production method for a lactic acid bacteria fermented poplar flower oral liquid. The method includes: taking 80-100mL of poplar flower water, 3-5g of soybean meal, 3-5g of brown sugar and 1.5-2.5g of peptone; coordinating the raw materials, conducting high-pressure sterilization, inoculating lactic acid bacteria accounting for 1% of the weight of the raw materials, and carrying out anaerobic fermentation at 37DEG C for 48h, thus obtaining the oral liquid. According to the invention, lactic acid bacteria are employed to ferment poplar flower water, at the end of fermentation, the fermentation broth contains two effective ingredients, i.e. lactic acid bacteria and fermentation type poplar flower extract. During application, the product can give play to the intestinal flora regulating, animal immunity enhancing and pathogenic microorganism inhibiting effects of lactic acid bacteria, and also can bring the poplar flower&#39;s efficacy of tonifying spleen and nourishing stomach, resolving dampness and stopping dysentery, relieving diarrhea with astringents, clearing away heat and toxic materials into play. Also, after fermentation in vitro, poplar flowers are easier to absorb, thereby better achieving the treatment purpose. The drug involved in the invention has the advantages of treatment of both symptoms and root causes, rapid efficacy, pure green and no residue, and excellent curative effect. 167 cases of clinical tests show that the total effective rate reaches 97.0%.
The canonical Wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), wound healing, and Alzheimer&#39;s disease. Elevated plasma homocysteine (HCy), which results from folate (folic acid, FA) deficiency, the mood-stabilizing drug lithium (Li), and alcohol (ethanol) are linked to the induction of human congenital heart and neural tube defects. FA supplementation ameliorates the observed developmental errors in the Li-HCy, or alcohol-exposed mouse embryos and normalized heart function. Li, HCy or Wnt3A suppress Wnt-modulated Hex and Islet-1 expression. FA protects from the gene misexpression that is induced by all three factors. Administration of myo-inositol with FA synergistically enhances the protective effect.
The invention relates to tetracycline compounds having the following formulae &lt;FORM:1065716/C2/1&gt; in which X is H or CH3, X1 is OH or X and X1 together are methylene, or X1 represents a second bond connecting C6 and C5a, X2 is H or OH, X being CH3 when the C6-C5a bond is a single bond and/or X2 is OH and Y is H or Cl; and Z is H, Cl or F, X being CH3 when the 6-5a bond is a single bond and Z is H, or Z is halogen when X and X1 are together methylene; and when X1 is OH, the compound III may be in its 4-6 hemiketal form. &lt;FORM:1065716/C2/2&gt; wherein X, X1, X2 and Y have the aforesaid meanings &lt;FORM:1065716/C2/3&gt; wherein Z is H, Cl or F, X is CH3 or H, X2 is OH or H, with the proviso that X is CH3 when Z is H or X2 is OH; Y is H or Cl.  Also their salts.  Compounds of formula (A) are produced by reacting a compound of formula &lt;FORM:1065716/C2/4&gt; in which X, X1, X2, Y and Z have the aforesaid meanings, the 6-5a bond being a single bond, or in which the Z is halo and X1 is an oxygen connected to the 6 and 12 positions in a hemiketal bond, with a hydrocarbon dicarboxylic acid haloimide, e.g. N-chlorosuccinimide and, if X1 in compound III is a bond in the 6-5a position, dehydrating the product in which X1 is OH or an oxygen connected to C6 and C4 in a hemiketal bond.  Compounds of formula (B) are produced by reducing compounds of formula (A), e.g. with alkali metal hydrosulphite in aqueous alcohol.  The salts may be pharmaceutically acceptable, e.g. the sodium, potassium, magnesium, calcium, aluminium, zinc, iron and magnesium; metal chelates salts with amines.  Barium and strontium salts may be used in the isolation and purification of these compounds.
PURPOSE:To provide the titled remedying water composed of a specific Ag&lt;+&gt; ion water and capable of promoting the recovering mechanism of living cell based on the mechanism of natural biosystem. CONSTITUTION:The objective remedying water for the disease of the mucosa of digestive organs and conjunctivas contains an Ag&lt;+&gt; ion water having a pH of &gt;=8 and an Ag&lt;+&gt; ion concentration of 0.1-10ppm (preferably having an electri cal conductivity of 250-450muupsilon/cm&lt;3&gt; and dissolved oxygen content of 6-9ppm and containing activated oxygen). It has bacteriostatic and bactericidal effect against pathogenic bacteria. It is colorless, odorless and non-irritant and exhibits rapid activity without giving any damage to the mucosa of digestive organs and keratoconjunctival tissue. The adjustment of the pH of the remedy water to &gt;=8 is effective in preventing the adsorption of Ag&lt;+&gt; ion to protein, preventing the lowering of the catalytic action of Ag&lt;+&gt; ion in the presence of protein and enabling the free permeation of Ag&lt;+&gt; ion through the cytomembrane of the objective bacterial cell or damaged cell. The water can be administered orally or as an ophthalmic solution without irritation.
Immunostimulatory sequence-specific RNA oligonucleotides corresponding to 3&#39; terminal sequences of single-stranded minus-sense RNA genomic RNAs are provided. Also provided are compositions and methods relating to an immunostimulatory 4-mer RNA motif provided as 5&#39;-C/U-U-G/U-U-3&#39;. Incorporation of this short RNA motif is sufficient to confer new and altered immunostimulatory properties in new and existing oligonucleotides, including CpG oligodeoxynucleotides. Also provided are methods for use of the immunostimulatory RNA oligonucleotides and DNA:RNA chimeric oligonucleotides of the invention to induce an immune response in vitro and in vivo, as well as to treat allergy, asthma, infection, and cancer in a subject. Single-stranded oligoribonucleotides of the invention are believed to signal through a Toll-like receptor (TLR) chosen from TLR9, TLR8, TLR7, and TLR3. The oligoribonucleotides can also be used in a method to screen for TLR antagonists.
PURPOSE: A pharmaceutical composition containing glyoxalase fusion protein is provided to prevent and treat neurodegenerative disease such as brain ischemia. CONSTITUTION: A glyoxalase fusion protein comprises 9-15 amino acid residues. The cell permeability efficiency is improved by covalent bond of a transport domain to the end of glyoxalase. The transport domain is HIV Tat 49-57 residu, oligolysine, oligoarginine, or oligo(lysine, arginine). The glyoxalase is glyoxalase I or glyoxalase II. The glyoxalase fusion protein has amino acid sequence of sequence number 9 or 11. A pharmaceutical composition for preventing and treating neurodegenerative diseases such as diabetes, Parkinson&#39;s disease, and Alzheimer&#39;s diseases, and nervous disease such as brain ischemia contains the glyoxalase fusion protein as an active ingredient and pharmaceutically acceptable carrier.
The new compounds cadmium butanesulphonate, cadmium p-carbomethoxybenzenesulphonate, cadmium p-carboxybenzenesulphonate, cadmium methanesulphonate, cadmium p-anisylsulphonate, cadmium p-nitrobenzenesulphonate, cadmium 2-propylsulphonate and cadmium p-thioanisylsulphonate are prepared by adding cadmium oxide to a hot stirred aqueous solution of the sulphonic acid using the theoretical molar ratio of the reactants or a slight excess of the acid.  The hydrated salts thus obtained may be dehydrated by vacuum drying.ALSO:Anthelmintic compositions suitable for administration to pigs comprise a water-soluble camdium salt of a sulphonic acid and a physiologically acceptable organic or inorganic acid in an amount sufficient to give in solution a pH of from 3 to 6.5.  The salts may be aromatic salts of the formula &lt;FORM:0932962/VI/1&gt; wherein R2 is a hydrogen or halogen atom or a lower (C1-8) alkyl or alkoxy, hydroxy, amino, nitro, carboxy, carbalkoxy or mercapto or lower alkyl thio radical or aliphatic salts of the formula [R1-SO3]2Cd, wherein R1 is a straight or branched chain C1-6 alkyl radical. Suitable acids are hydrochloric, sulphuric, acetic, citric, lactic, benzoic, p-toluene sulphonic and benzene and methane sulphonic acids.  The compositions may be in the form of solid or aqueous concentrates and may also contain flavouring agents and nutritional factors, e.g. one or all of the b -vitamins.  The preparation of several new cadmium sulphonates is described (see Group IV (b)).
PURPOSE:To predict the distribution coefft. of a material having a ring which does not contain satd. carbon by giving at least 5 atomic group constants to a heteroatomic group constituting the ring and an atomic group bonded to the ring and combining these constants. CONSTITUTION:The contribution component pi&#39; by the partial structural part consisting of the atoms with which the distance from the substitution position among the change rates pi of the logarithmic value of the is distribution coefft. when one atomic group is substd. with the arom. ring is in n (1&lt;=n&lt;=10) pieces range in the number of bonds, the ratio alpha at which one atomic group changes the pi&#39; of the other atomic group, the electronic substitution constant sigma of one atomic group, the scale rho at which the pi value of one atomic group changes according to the sigma value of the other atomic group, and the change rate F of the logarithmic value of the distribution coefft. when &gt;=2 atomic groups are substd. in proximity to each other are given and the distribution coefft. P of the objective material is calculated by the equation 1. The distribution coefft. of polysubstd. benzene, etc., is predicted with good accuracy in this way.
This invention provides a method for long term pain relief. The method is basically using five novel herbal compositions, adjust the dosages according to the reason of the pain and the situation of the patient&#39;s body. The herbal composition is Corydalis Yanhusuo, E Zhu (Curcuma kwangsiensis, Rhizome), Cili Fruit (Rosa roxburghii) Extract, DL-alpha-Lipoic acid. It is preferred to diagnosis the disease and check the patient&#39;s body condition in advance. and therapeutic effects on inflammatory, sprain, gout and rheumatic arthritic diseases in human. Especially for body joint. The herbal compositions of the present invention can be used as a pharmaceutical composition, a dietary supplement or a feed. This invention also provides processes for making the herbal compositions.
A nail drying apparatus and method by which any commercially available nail polish of any colour can be dried after being applied to a person&#39;s finger or toe nails, consists of a photo-reactive coating and a device that generates ultraviolet radiation. The photo-reactive coating is applied over the wet nail polish and then irradiated with safe dosages of ultraviolet radiation causing the nail polish to dry in a few minutes. A UV lamp suitable for drying finger nails or toe nails varnished is illustrated in Fig 1. The finger nails are placed in the gap between a switch and a fluorescent tube. An eyeshield 18 is provided. &lt;IMAGE&gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a core that has undergone a certain enrobing treatment such as an enrobed tablet core.  &lt;P&gt;SOLUTION: An enrobed a core, such as a tablet core, that has a coating made of one or more patterned films each having portions that are visually distinct (e.g., differently colored) from one another and having a transition line segment between these visually distinct portions. At least a portion of an outer surface of the core is covered with the film or films, such that the transition line segments form a substantially continuous transition line. Where the patterned films are bi-colored, the resulting enrobed core can be bi-colored, or the resulting enrobed core can have a coating with at least four visually distinct portions alternately arranged thereon, thereby forming a checkered pattern on the coating. In either case, the film seam of the coating is different from the transition line of the coating.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
FromJanuary 2023 to July 2024, 50 PD patients and 50 health control groups were collected. All subjects were from the Parkinson\&#39;s outpatient clinic and ward of the Department of Neurology, Suzhou Hospital Affiliated to Anhui Medical University. This study was approved by the Medical Ethics Committee of Suzhou Municipal Hospital and signed an informed consent form. The gender, age, identity registration, place of origin, marital status, education level, occupation, smoking, drinking, occupational exposure, body mass index, home address and contact information of the patients were collected for detailed registration. Current medical history, past history, family history, medication use, physical examination, previous relevant auxiliary examination results, etc. Evaluation scales: H-Y Staging Scale, UPDRS Scale, Breg Balance Scale, MMSE Intelligence Scale, MoCA Scale, SDS Depression Self-Rating Scale, SAS Anxiety Self-Rating Scale, PDSS Parkinson\&#39;s Disease Sleep Scale. Peripheral blood of patients and control groups were sampled to determine the levels of vitamin D, Treg and Th17. PD patients were divided into vitamin D deficiency group and vitamin D non-deficiency group according to the detection of vitamin D. Vitamin D deficiency group was randomly divided into intervention group and non-intervention group. The intervention group was supplemented with vitamin D, and the non-intervention group was not treated. The above scale and peripheral blood vitamin D, Treg and Th17 levels were evaluated after 3 months of follow-up and compared with the pre-intervention and non-intervention groups. Statistical analysis was carried out using SPSS26.0 and GraphPad Prism v.9.
PURPOSE:An antibacterial agent having high bacterial action especially on tubercle bacillus, comprising 2,2&#39;-dithiobisbenzamide derivative as an active ingredient. CONSTITUTION:A drug for infectious diseases by bacteria, such as tuberculosis, etc., containing a compound shown by the formula (R1 is 1-15C substituted or unsubstituted alkylamino, 2-10C dialkylamino, substituted or unsubstituted phenylamino, substituted or unsubstituted cyclohexylamino, substituted piperazino, etc.; R2 is H, or halogen) as an active ingredient. A tablet, powder, capsule, injection, etc. may be cited as the dosage form. Since the compound shown by the formula as the active ingredient is a stable compound having extremely high LD50 value, it can be administered in a considerably large amount, and the minimum effective amount is 500-100mg/adult/time.